This bill directs the Secretary of Health and Human Services to ensure that references to opioid overdose reversal drugs in HHS grant regulations and guidance are not limited to naloxone but are inclusive of any opioid overdose reversal drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act for emergency treatment of opioid overdose. It applies to future regulations and guidance for any HHS grant program addressing opioid misuse and use disorders and requires HHS to update certain pre‑existing references within one year.
Why this matters: the change removes a potential regulatory obstacle that could prevent grantees from using federal grant funds to procure newly FDA‑approved reversal agents. That matters to state and Tribal grantees, harm‑reduction programs, first responders, and manufacturers developing alternative antagonists or delivery systems, without creating new funding or changing FDA approval standards.
At a Glance
What It Does
The bill requires HHS to ensure that any reference to an opioid overdose reversal drug in regulations or guidance for grant programs addressing opioid misuse is interpreted to include any opioid overdose reversal drug approved under section 505 of the FD&C Act for emergency treatment. It also directs HHS to update specified existing references in its grant program regulations and guidance within one year.
Who It Affects
Directly affects HHS grant programs that fund opioid response activities, the State and Tribal grantees that receive those awards, public health clinics and harm‑reduction providers that implement programs, and manufacturers of opioid reversal agents seeking federal markets. First responders and community distribution sites that rely on grant funding for supplies will be operationally affected.
Why It Matters
By making grant guidance product‑neutral and tied to FDA 505 approvals, the bill reduces regulatory lag between FDA approval of new reversal agents and their eligibility under federal grant rules. That increases program flexibility and could accelerate adoption of alternative products, but it does not provide purchase funding or change FDA regulatory standards.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a simple administrative rule: when HHS writes or updates regulations or guidance for any grant program that addresses opioid misuse and opioid use disorders, any language that mentions an opioid overdose reversal drug (for example, naming naloxone) must be read to include any opioid overdose reversal drug that the FDA has approved under the standard drug approval pathway (section 505 of the FD&C Act) for emergency treatment of a known or suspected opioid overdose. In short, the statute makes grant language technology‑neutral and tied to FDA approval status.
The statute applies to both new and existing HHS materials. For regulations and guidance issued after enactment, HHS must ensure the inclusive interpretation “as appropriate.” For guidance and regulations already on the books, the bill orders HHS to update those references within one year so they explicitly encompass any 505‑approved reversal agent.
The bill pinpoints two funding streams where prior references must be updated: the State and Tribal opioid response grants under section 1003 of the 21st Century Cures Act and the section 516 Public Health Service Act grants for priority substance use disorder prevention needs.Practically, the change removes a textual constraint in federal grant documents that could have been read to limit allowable grant‑funded purchases to naloxone specifically. It does not change what products the FDA approves, does not alter clinical standards of care, and does not appropriate money for procurement.
Instead, it aligns grant eligibility and program guidance with FDA approvals so that when FDA clears a new emergency reversal agent via the traditional 505 pathway, HHS grant programs can treat that agent as within scope of allowable grant activities without separate regulatory amendments.Implementation will be administrative: HHS will need to revise regulatory text, grant award terms, allowable use language in program guidance, and any model procurement or reporting templates. Grantees should expect new flexibility but also the need to update local policies, training, and inventory management if they choose to adopt non‑naloxone reversal agents.
The Five Things You Need to Know
The bill requires HHS to interpret references to opioid overdose reversal drugs in grant regulations and guidance as inclusive of any drug approved under section 505 of the FD&C Act for emergency treatment of opioid overdose.
It explicitly ties the definition of “inclusive” to FDA approval under the section 505 approval pathway, not to Emergency Use Authorizations or state emergency authorizations.
HHS must update all existing references that predate the bill within one year of enactment.
The bill singles out two grant streams for required updates: State and Tribal response to opioid use disorders grants under section 1003 of the 21st Century Cures Act and the section 516 Public Health Service Act grants.
The statute changes eligibility language and administrative guidance only; it does not appropriate funds, set reimbursement rates, or alter FDA’s approval standards.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s name: the Halting the Epidemic of Addiction and Loss Act of 2025. This is ceremonial but useful shorthand for administrative references and internal HHS tracking when carrying out the statute's directives.
Ensure inclusive references in new regulations and guidance
Directs the Secretary of HHS to make sure that when the Department issues regulations or guidance for any grant program addressing opioid misuse or opioid use disorders, any reference to an opioid overdose reversal drug (for example, naming naloxone) is to be read as inclusive of any opioid overdose reversal drug approved under section 505 of the FD&C Act for emergency treatment of a known or suspected opioid overdose. Practically, this requires HHS to use language or definitional clauses in future rulemaking and guidance that avoid singling out a single product by name and instead tie eligibility to FDA approval status.
One‑year deadline to update existing references
Requires HHS to update pre‑existing regulations and guidance described in subsection (b)(2) within one year of enactment so that those documents likewise read as inclusive of any FDA 505‑approved reversal agent. The one‑year clock creates an administrative deadline that will drive internal rule‑clearing, interagency review, and amendments to grant guidance, funding opportunity announcements, and award terms and conditions.
Scope of existing references to be updated (enumerated grant programs)
Specifies which existing references must be updated: any pre‑enactment reference to an opioid overdose reversal drug in HHS regulations or guidance that is included in (i) the State and Tribal response to opioid use disorders grant program under section 1003 of the 21st Century Cures Act (commonly called State Opioid Response and Tribal Opioid Response grants) or (ii) the section 516 PHSA grant program for priority substance use disorder prevention needs. By naming these programs, the statute focuses immediate administrative work on two sizable funding streams that shape statewide and regional overdose response activities.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People at risk of opioid overdose and their communities — because grantees can adopt newly FDA‑approved reversal agents under federal grant programs without waiting for separate HHS rule changes, potentially increasing access to alternative delivery forms or antagonists.
- State and Tribal grantees of federal opioid response grants — they gain procurement flexibility and clearer allowable‑use authority for grant funds when considering non‑naloxone reversal products.
- Public health implementers and harm‑reduction programs — they receive clearer federal guidance that supports piloting or scaling different reversal agents and delivery systems as they become FDA‑approved.
- Manufacturers developing alternative opioid antagonists or novel delivery systems — the bill reduces a regulatory barrier to market access under federal grants by ensuring product‑neutral grant language tied to FDA 505 approvals.
Who Bears the Cost
- HHS — must allocate staff time and administrative resources to review and revise regulations, guidance, funding opportunity announcements, and award terms; legal and interagency review will consume budgeted administrative capacity.
- State, Tribal, and local grantees — will face implementation costs (procurement changes, personnel training, updating protocols and standing orders, inventory management) if they choose to adopt different reversal agents.
- Small community providers and harm‑reduction organizations — may bear short‑term increased costs and logistical burdens if newer approved agents are more expensive or require different storage/administration than naloxone.
- Program administrators and grant managers — must update compliance, monitoring, and reporting frameworks to account for new product types and ensure allowable uses align with grant terms.
Key Issues
The Core Tension
The central tension is between enabling rapid adoption of new, FDA‑approved opioid reversal technologies by making federal grant language product‑neutral, and preserving practical, equitable public‑health delivery: product neutrality promotes innovation and flexibility, but without funding, clear clinical guidance, or attention to cost and logistics it may widen disparities in access and complicate procurement and training for overstretched programs.
The bill is narrow in legislative method but broad in practical effect; it uses inclusive language and FDA 505 approval as the gating criterion rather than prescribing or endorsing any specific product. That approach resolves one category of regulatory friction — named references to naloxone in guidance — but leaves open several implementation questions.
First, tying inclusivity to section 505 approvals excludes non‑505 pathways (for example, Emergency Use Authorizations, state‑level emergency authorizations, or drugs authorized under other statutory mechanisms) unless and until the product also obtains 505 approval. Grantees that previously relied on such temporary authorizations may find themselves in a gray area until FDA provides full approval.
Second, the statute does not supply funding for procurement or training. If an FDA‑approved alternative is substantially more expensive, or requires different storage or administration, programs will need to reallocate existing grant funds or seek other sources to adopt it.
That raises equity concerns: jurisdictions with limited budgets — rural, Tribal, or smaller community programs — may lag in adoption. Finally, “as appropriate” language and the administrative one‑year deadline give HHS discretion but also create uncertainty about the scope of updates (how comprehensive the revisions must be) and the degree of coordination HHS must undertake with FDA, CMS, and other agencies on coverage, reimbursement, and clinical guidance.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.